Xeris Pharmaceuticals Inc (XERS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.05B
Last updated: Nov 17, 2026 at 4:41 PM ET
Xeris Pharmaceuticals Inc (XERS) Stock Chart
Xeris Pharmaceuticals (XERS) has a latest price of $16.80 on Nov 17, 2026, 1.1% below its 52-week high of $16.98. Its price rose 134.0% over the past 12 months. The month-end price fell 43.6% since Jun 2018, a compound annual decline of 6.6%.
Price Chart
From Jun 2018 to Oct 2026, its highest month-end close was $25.70 in Aug 2018 and its lowest $1.24 in Jan 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart XERS with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for XERS.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 91.3%, and over 6 months it rose 183.8%. The month-end price rose 485.2% over the 3 years through Oct 2026, a compound annual rate of 80.2%.
| Period | Change |
|---|---|
| 1 month | +53.4% |
| 3 months | +91.3% |
| 6 months | +183.8% |
| 12 months | +134.0% |
| 12 months, with dividends | +134.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +485.2% | +80.2% |
| 5 years | +475.8% | +41.9% |
| Since Jun 2018 | -43.6% | -6.6% |
Price by Year
Its best calendar year was 2025, when the price rose 131.6%, and its weakest was 2019, when it fell 58.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $10.71 | +36.4% |
| 2025 | $7.85 | +131.6% |
| 2024 | $3.39 | +44.3% |
| 2023 | $2.35 | +76.7% |
| 2022 | $1.33 | -54.6% |
| 2021 | $2.93 | -40.4% |
| 2020 | $4.92 | -30.2% |
| 2019 | $7.05 | -58.5% |
Trading Range
The price is 56.5% above its 50-day average of $10.73 and 112.0% above its 200-day average of $7.92.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $16.80 | |
| 52-week high | $16.98 | -1.1% |
| 52-week low | $5.25 | +220.0% |
| 50-day average | $10.73 | +56.5% |
| 200-day average | $7.92 | +112.0% |
Price Risk
Over 3 years, its largest fall from a peak was 47.2%.
| Measure | Value |
|---|---|
| 1-year beta | 0.12 |
| Largest fall, 1 year | -34.9% |
| Largest fall, 3 years | -47.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About XERS
What is XERS's 1-year price change?
Xeris Pharmaceuticals's price rose 134.0% over the past 12 months. With dividends included, the 12-month total return was 134.0%.
What is XERS's 5-year price change?
Xeris Pharmaceuticals's month-end price rose 475.8% over the 5 years through Oct 2026, a compound annual rate of 41.9%. These figures leave out dividends.
What is XERS's 52-week high and low?
Xeris Pharmaceuticals's 52-week high is $16.98 and its 52-week low is $5.25. Its latest price of $16.80 on Nov 17, 2026 is 1.1% below the high.
What is XERS's beta?
Xeris Pharmaceuticals's 1-year beta against the S&P 500 is 0.12, so its price has shown little link to the market's moves over the past year. Its largest fall from a peak over the past year was 34.9%.
Is the XERS chart free?
Yes. Advanced Charting for XERS is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
XERS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors